Acceptability and adherence to Isoniazid preventive therapy in HIV-infected patients clinically screened for latent tuberculosis in Dar es Salaam, Tanzania

Grace A Shayo, Candida Moshiro, Said Aboud, Muhammad Bakari, Ferdinand M Mugusi, Grace A Shayo, Candida Moshiro, Said Aboud, Muhammad Bakari, Ferdinand M Mugusi

Abstract

Background: Proper adherence to isoniazid preventive therapy (IPT) may depend upon the results of tuberculosis (TB) screening test and patients' understanding of their risk of developing active TB. We conducted a study to assess the acceptability, adherence and completion profile of IPT among HIV-infected patients who were clinically screened for latent TB Infection (LTBI).

Methods: A multicenter observational study was conducted in Dar es Salaam, Tanzania between February 2012 and March 2014. HIV-infected patients 10 years or older were clinically screened using a validated symptom-based screening tool to rule out active TB. Patients found to have no symptoms in the screening tool were given 300 mg of isoniazid (INH) daily for 6 months. Patients were followed up monthly at the National and Municipal hospital HIV clinics for INH refill and assessment of treatment adherence. Adherence was defined as consumption of 90 % or more of the monthly prescription of INH.

Results: All 1303 invited patients agreed to participate in the study. Of 1303 invited HIV-infected patients, 1283 (98.5 %) were recruited into the study. Twenty eight (2.2 %) did not complete treatment. Those who did not complete the treatment were exclusively adults aged 18 years or older, p = 0.302. The overall mean (±SD) adherence was 98.9 % (±2.9). Adherence level among children aged <18 years (92.2 %) was significantly lower than adherence level among patients aged 18-29 years (98.3 %), 30-49 years (98.8 %) and ≥ 50 years (98.5), p-value = 0.011. Sex, occupation, socio-economic status, duration of HIV infection, being on antiretroviral drugs (ARV) and duration of ARV use were not associated with adherence.

Conclusion: IPT is highly accepted by HIV infected patients. Patients demonstrated high level of adherence to IPT. The level of adherence among children was slightly lower than that among adults. IPT non-completers were exclusively adults. Children might need adult supervision in taking IPT.

Figures

Fig. 1
Fig. 1
Patient recruitment and retention flow chart

References

    1. WHO. Global Tuberculosis Report 2014 Geneva, Switzerland; 2014. Available from: . Accessed February 10, 2015.
    1. WHO. Guidelines for intensified case finding isoniazid preventive therapy for people living with HIV in resource constrained settings. 2011. Available from . Acessed February 10, 2015.
    1. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons (Review) Cochrane Libr. 2010;1:1–82.
    1. Golub JE, Paul P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631–636. doi: 10.1097/QAD.0b013e328327964f.
    1. Date AA, Vitoria M, Granich R, Banda M, Youssef M, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010;88:253–259. doi: 10.2471/BLT.09.066522.
    1. Li J, Munsiff SS, Tarantino T, Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Infect Dis. 2010;14(4):e292–297. doi: 10.1016/j.ijid.2009.05.007.
    1. Munseri PJ, Talbot EA, Mtei L, Von Reyn CF. Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania. Int J Tuberc Lung Dis. 2008;12(9):1037–1041.
    1. Hiransuthikul N, Nelson KE, Hiransuthikul P, Vorayingyong A, Paewplot R. INH preventive therapy among adult HIV-infected patients in Thailand. Int J Tuberc Lung Dis. 2005;9(July 2004):270–5.
    1. Berhe M, Demissie M, Tesfaye G. Isoniazid Preventive Therapy Adherence and Associated Factors among HIV Positive Patients in Addis Ababa. Ethiopia Adv Epidemiol. 2014;2014:1–6. doi: 10.1155/2014/230587.
    1. Mindachew M, Deribew A, Tessema F, Biadgilign S. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis. BMC Public Health. 2011;11(1):916. doi: 10.1186/1471-2458-11-916.
    1. Makanjuola T, Taddese HB, Booth A. Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. PLoS One. 2014;9(2):e87166. doi: 10.1371/journal.pone.0087166.
    1. Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, Van Crevel R, et al. Adherence to isoniazid preventive therapy in Indonesian children: a quantitative and qualitative investigation. BMC Res Notes. 2012;5:7. doi: 10.1186/1756-0500-5-7.
    1. Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17:1–6. doi: 10.11604/pamj.2014.17.26.2641.
    1. Namuwenge PM, Mukonzo JK, Kiwanuka N, Wanyenze R, Byaruhanga R, Bissell K, et al. Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda. Trans R Soc Trop Med Hyg. 2012;106:84–89. doi: 10.1016/j.trstmh.2011.10.015.
    1. Tanzania Ministry of Health and Social Welfare. Manual for National Tuberculosis and Leprosy Program 2006. Available from: Acessed on February 27, 2015.
    1. Tanzania National AIDS Control Program. Guidelines for the management of HIV and AIDS 2009. Available from Acessed on May 5, 2013.
    1. Shayo GA, Minja LT, Egwaga S, Bakari M, Mugusi FM. Symptom-based screening tool in ruling out active tuberculosis among HIV-infected patients eligible for isoniazid preventive therapy in Tanzania. Trop Med Int Health. 2014;19(6):726–33.
    1. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how to use principal components analysis. Health Policy Plan. 2006;21(6):459–468. doi: 10.1093/heapol/czl029.
    1. Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010;24(Suppl 5):S49–S56. doi: 10.1097/01.aids.0000391022.95412.a6.
    1. Gust DA, Mosimaneotsile B, Mathebula U, Chingapane B, Gaul Z, Pals SL, et al. Risk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana. PLoS One. 2011;6(4):e18435. doi: 10.1371/journal.pone.0018435.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren